Unknown

Dataset Information

0

Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants.


ABSTRACT: In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducing malaria's impact. Sanaria® PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria-naïve and experienced adults in the United States and Mali and protective against controlled human malaria infection with Pf in the United States and field transmission of Pf in Mali, but had not been assessed in younger age groups. We, therefore, evaluated PfSPZ Vaccine in 93 Tanzanians aged 45 years to 6 months in a randomized, double-blind, normal saline placebo-controlled trial. There were no significant differences in adverse events between vaccinees and controls or between dosage regimens. Because all age groups received three doses of 9.0 × 105 PfSPZ of PfSPZ Vaccine, immune responses were compared at this dosage. Median antibody responses against Pf circumsporozoite protein and PfSPZ were highest in infants and lowest in adults. T-cell responses were highest in 6-10-year olds after one dose and 1-5-year olds after three doses; infants had no significant positive T-cell responses. The safety data were used to support initiation of trials in > 300 infants in Kenya and Equatorial Guinea. Because PfSPZ Vaccine-induced protection is thought to be mediated by T cells, the T-cell data suggest PfSPZ Vaccine may be more protective in children than in adults, whereas infants may not be immunologically mature enough to respond to the PfSPZ Vaccine immunization regimen assessed.

SUBMITTER: Jongo SA 

PROVIDER: S-EPMC6553883 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and Differential Antibody and T-Cell Responses to the <i>Plasmodium falciparum</i> Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants.

Jongo Said A SA   Church L W Preston LWP   Mtoro Ali T AT   Chakravarty Sumana S   Ruben Adam J AJ   Swanson Phillip A PA   Kassim Kamaka R KR   Mpina Maximillian M   Tumbo Anneth-Mwasi AM   Milando Florence A FA   Qassim Munira M   Juma Omar A OA   Bakari Bakari M BM   Simon Beatus B   James Eric R ER   Abebe Yonas Y   Kc Natasha N   Saverino Elizabeth E   Gondwe Linda L   Studer Fabian F   Fink Martina M   Cosi Glenda G   El-Khorazaty Jill J   Styers David D   Seder Robert A RA   Schindler Tobias T   Billingsley Peter F PF   Daubenberger Claudia C   Sim B Kim Lee BKL   Tanner Marcel M   Richie Thomas L TL   Abdulla Salim S   Hoffman Stephen L SL  

The American journal of tropical medicine and hygiene 20190601 6


In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducing malaria's impact. Sanaria<sup>®</sup> PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved <i>Plasmodium falciparum</i> (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria-naïve and experienced adults in the United States and Mali and protective against controlled human malaria infection with Pf in the U  ...[more]

Similar Datasets

| S-EPMC5077156 | biostudies-literature
| S-EPMC5214067 | biostudies-literature
| S-EPMC6090339 | biostudies-literature
| S-EPMC1592691 | biostudies-literature
| S-EPMC5021941 | biostudies-literature
| S-EPMC3064590 | biostudies-literature
| S-EPMC7297289 | biostudies-literature
| S-EPMC50088 | biostudies-other
| S-EPMC2772840 | biostudies-literature
| S-EPMC6803168 | biostudies-literature